<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9231">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05702398</url>
  </required_header>
  <id_info>
    <org_study_id>19792</org_study_id>
    <nct_id>NCT05702398</nct_id>
  </id_info>
  <brief_title>Pilot Trial of Supplemental Vitamin A and Nicotinamide</brief_title>
  <official_title>Pilot Trial of Supplemental Vitamin A and Nicotinamide and Levels of Blood Vitamin A and Nicotinamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhode Island Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to assess the feasibility and safety of oral nicotinamide&#xD;
      (NAM; a derivative of vitamin B3 [niacin]) and vitamin A in a high-risk population of kidney&#xD;
      transplant recipients with a history of skin cancer to generate preliminary data for future&#xD;
      cancer prevention clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2023</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Blood Vitamin A and Nicotinamide Levels</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Skin Cancer</condition>
  <condition>Kidney Transplant Recipients</condition>
  <arm_group>
    <arm_group_label>Vitamin A &amp; Nicotinamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1,000 μg retinyl palmitate and 500 mg NAM twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical placebo pills twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin A</intervention_name>
    <description>1,000 μg retinyl palmitate twice a day for 6 months</description>
    <arm_group_label>Vitamin A &amp; Nicotinamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotinamide</intervention_name>
    <description>500 mg NAM twice a day for 6 months</description>
    <arm_group_label>Vitamin A &amp; Nicotinamide</arm_group_label>
    <other_name>Niacin (Vitamin B3)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Other: Placebo</intervention_name>
    <description>Identical placebo pills twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years old or greater;&#xD;
&#xD;
          -  Either History of 2 or more histologically confirmed invasive cutaneous SCCs in the&#xD;
             past 2 years or&#xD;
&#xD;
          -  At least one previously billed Healthcare Common Procedure Coding System code 17004&#xD;
             (destruction of 15 or more benign or premalignant lesions of the integumentary&#xD;
             system);&#xD;
&#xD;
          -  Understands, reads, and writes English proficiently.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Liver disease;&#xD;
&#xD;
          -  Active peptic ulcer disease;&#xD;
&#xD;
          -  Recent myocardial infarction;&#xD;
&#xD;
          -  Hypotension;&#xD;
&#xD;
          -  Internal malignancy within past 5 years;&#xD;
&#xD;
          -  Renal impairment with eGFR&lt;15 mL/min/1.73 m2;&#xD;
&#xD;
          -  Being unable for follow up due to social reasons;&#xD;
&#xD;
          -  Gorlin's syndrome or other genetic skin cancer syndrome;&#xD;
&#xD;
          -  Huge number of current skin cancers;&#xD;
&#xD;
          -  Metastatic SCC or invasive melanoma within the past 5 years;&#xD;
&#xD;
          -  Pregnancy or lactation;&#xD;
&#xD;
          -  Need for ongoing carbamazepine use (which could have a possible interaction with NAM);&#xD;
&#xD;
          -  Use of acitretin or other oral retinoids within the past 6 months;&#xD;
&#xD;
          -  Use of supplemental NAM, niacin, vitamin A, or beta carotene within the past 6 months;&#xD;
&#xD;
          -  Field treatment for actinic keratoses (AKs) within the previous 4 weeks;&#xD;
&#xD;
          -  Use of topical steroids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eunyoung Cho, ScD</last_name>
    <phone>401-863-5895</phone>
    <email>Eunyoung_Cho@brown.edu</email>
  </overall_contact>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>January 18, 2023</study_first_submitted>
  <study_first_submitted_qc>January 18, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2023</study_first_posted>
  <last_update_submitted>January 18, 2023</last_update_submitted>
  <last_update_submitted_qc>January 18, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

